JACC:植入式监护仪可有效预警急性心梗的发生

2019-04-28 不详 MedSci原创

急性冠脉综合征(ACS)很难通过临床症状及时发现,本研究的目的旨在详细描述ALERTS临床试验中的可快速提醒患者ST段异常的植入式心脏监护仪的效果。本研究将907名高危ACS患者随机分成对照组(仪器失活)和实验组,主要终点事件是无系统相关并发症(>90%)。复合主要疗效终点为心脏/不明原因死亡、新发Q波心肌梗死或诊断至治疗间隔时间大于2h。与对照组相比,7天内的疗效终点事件在实验组中并无明显

急性冠脉综合征(ACS)很难通过临床症状及时发现,本研究的目的旨在详细描述ALERTS临床试验中的可快速提醒患者ST段异常的植入式心脏监护仪的效果。


本研究将907名高危ACS患者随机分成对照组(仪器失活)和实验组,主要终点事件是无系统相关并发症(>90%)。复合主要疗效终点为心脏/不明原因死亡、新发Q波心肌梗死诊断至治疗间隔时间大于2h。与对照组相比,7天内的疗效终点事件在实验组中并无明显降低([3.8%] vs[4.9%],p = 0.786),在90天的窗口期内,监护仪可以明显减少诊断至治疗间隔时间(51 min vs. 30.6 h; Pr [pt < pc] >0.999)。在扩展分析后,监护仪组患者的阳性预测值更高,假阳性率更低。


研究结果显示,该心脏预警装置可能有利于高危ACS患者识别无症状事件。


原始出处:

C. Michael et al.Implantable Cardiac Alert System for Early Recognition of ST-Segment Elevation Myocardial Infarction.JACC.2019 Apr.


本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1854374, encodeId=cf3618543e457, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Jul 11 14:57:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748746, encodeId=c0ef1e48746db, content=<a href='/topic/show?id=4087626564c' target=_blank style='color:#2F92EE;'>#植入式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62656, encryptionId=4087626564c, topicName=植入式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdca36191722, createdName=villahu, createdTime=Tue Mar 17 08:57:00 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308382, encodeId=67cc1308382e2, content=<a href='/topic/show?id=8323522e503' target=_blank style='color:#2F92EE;'>#急性心梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52275, encryptionId=8323522e503, topicName=急性心梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Tue Apr 30 01:57:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326195, encodeId=c5281326195ac, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Apr 30 01:57:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520578, encodeId=383c15205e870, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Tue Apr 30 01:57:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551151, encodeId=1c0c155115149, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Tue Apr 30 01:57:00 CST 2019, time=2019-04-30, status=1, ipAttribution=)]
    2019-07-11 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1854374, encodeId=cf3618543e457, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Jul 11 14:57:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748746, encodeId=c0ef1e48746db, content=<a href='/topic/show?id=4087626564c' target=_blank style='color:#2F92EE;'>#植入式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62656, encryptionId=4087626564c, topicName=植入式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdca36191722, createdName=villahu, createdTime=Tue Mar 17 08:57:00 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308382, encodeId=67cc1308382e2, content=<a href='/topic/show?id=8323522e503' target=_blank style='color:#2F92EE;'>#急性心梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52275, encryptionId=8323522e503, topicName=急性心梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Tue Apr 30 01:57:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326195, encodeId=c5281326195ac, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Apr 30 01:57:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520578, encodeId=383c15205e870, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Tue Apr 30 01:57:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551151, encodeId=1c0c155115149, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Tue Apr 30 01:57:00 CST 2019, time=2019-04-30, status=1, ipAttribution=)]
    2020-03-17 villahu
  3. [GetPortalCommentsPageByObjectIdResponse(id=1854374, encodeId=cf3618543e457, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Jul 11 14:57:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748746, encodeId=c0ef1e48746db, content=<a href='/topic/show?id=4087626564c' target=_blank style='color:#2F92EE;'>#植入式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62656, encryptionId=4087626564c, topicName=植入式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdca36191722, createdName=villahu, createdTime=Tue Mar 17 08:57:00 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308382, encodeId=67cc1308382e2, content=<a href='/topic/show?id=8323522e503' target=_blank style='color:#2F92EE;'>#急性心梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52275, encryptionId=8323522e503, topicName=急性心梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Tue Apr 30 01:57:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326195, encodeId=c5281326195ac, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Apr 30 01:57:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520578, encodeId=383c15205e870, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Tue Apr 30 01:57:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551151, encodeId=1c0c155115149, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Tue Apr 30 01:57:00 CST 2019, time=2019-04-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1854374, encodeId=cf3618543e457, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Jul 11 14:57:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748746, encodeId=c0ef1e48746db, content=<a href='/topic/show?id=4087626564c' target=_blank style='color:#2F92EE;'>#植入式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62656, encryptionId=4087626564c, topicName=植入式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdca36191722, createdName=villahu, createdTime=Tue Mar 17 08:57:00 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308382, encodeId=67cc1308382e2, content=<a href='/topic/show?id=8323522e503' target=_blank style='color:#2F92EE;'>#急性心梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52275, encryptionId=8323522e503, topicName=急性心梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Tue Apr 30 01:57:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326195, encodeId=c5281326195ac, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Apr 30 01:57:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520578, encodeId=383c15205e870, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Tue Apr 30 01:57:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551151, encodeId=1c0c155115149, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Tue Apr 30 01:57:00 CST 2019, time=2019-04-30, status=1, ipAttribution=)]
    2019-04-30 docwu2019
  5. [GetPortalCommentsPageByObjectIdResponse(id=1854374, encodeId=cf3618543e457, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Jul 11 14:57:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748746, encodeId=c0ef1e48746db, content=<a href='/topic/show?id=4087626564c' target=_blank style='color:#2F92EE;'>#植入式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62656, encryptionId=4087626564c, topicName=植入式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdca36191722, createdName=villahu, createdTime=Tue Mar 17 08:57:00 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308382, encodeId=67cc1308382e2, content=<a href='/topic/show?id=8323522e503' target=_blank style='color:#2F92EE;'>#急性心梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52275, encryptionId=8323522e503, topicName=急性心梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Tue Apr 30 01:57:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326195, encodeId=c5281326195ac, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Apr 30 01:57:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520578, encodeId=383c15205e870, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Tue Apr 30 01:57:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551151, encodeId=1c0c155115149, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Tue Apr 30 01:57:00 CST 2019, time=2019-04-30, status=1, ipAttribution=)]
    2019-04-30 jiyangfei
  6. [GetPortalCommentsPageByObjectIdResponse(id=1854374, encodeId=cf3618543e457, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Jul 11 14:57:00 CST 2019, time=2019-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1748746, encodeId=c0ef1e48746db, content=<a href='/topic/show?id=4087626564c' target=_blank style='color:#2F92EE;'>#植入式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62656, encryptionId=4087626564c, topicName=植入式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cdca36191722, createdName=villahu, createdTime=Tue Mar 17 08:57:00 CST 2020, time=2020-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308382, encodeId=67cc1308382e2, content=<a href='/topic/show?id=8323522e503' target=_blank style='color:#2F92EE;'>#急性心梗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52275, encryptionId=8323522e503, topicName=急性心梗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Tue Apr 30 01:57:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326195, encodeId=c5281326195ac, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Apr 30 01:57:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1520578, encodeId=383c15205e870, content=<a href='/topic/show?id=7a736264553' target=_blank style='color:#2F92EE;'>#植入#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62645, encryptionId=7a736264553, topicName=植入)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=832411313664, createdName=jiyangfei, createdTime=Tue Apr 30 01:57:00 CST 2019, time=2019-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551151, encodeId=1c0c155115149, content=<a href='/topic/show?id=e2c1e230796' target=_blank style='color:#2F92EE;'>#监护#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72307, encryptionId=e2c1e230796, topicName=监护)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=477814173963, createdName=bioon6, createdTime=Tue Apr 30 01:57:00 CST 2019, time=2019-04-30, status=1, ipAttribution=)]
    2019-04-30 bioon6

相关资讯

JACC:PCI可降低老年STEMI合并心源性休克患者死亡率

年龄大于等于75岁的老年人在ST段抬高型心肌梗死(STEMI)合并心源性休克后死亡率会增加。本研究的目的旨在评估经皮冠脉介入治疗(PCI)在老年STEMI合并心源性休克患者中的应用及其对住院死亡率的影响。本研究纳入了1999-2013年美国317728名STEMI合并休克的患者,其中年龄≥75岁的占35%,女性占53%。老年STEMI合并休克患者的诊断例数逐年减少,但是老年患者的PCI率逐年增加,

JAHA:阿托伐他汀可通过改善肾功能降低心血管风险

肾功能会随着年龄变大而降低,这种降低对肾和心血管疾病是一个很好的预测因子。他汀类药物可以降低心血管疾病风险,这可能会其对肾功能的益处有关。本研究的目的旨在评估阿托伐他汀对肾功能的影响,及其对心血管结局的影响。本研究分析了6个大型阿托伐他汀临床试验的数据,并对30621名患者的血清肌酐倒数的斜率代表肾功能的改变([Mg/DL]-1/y)进行了分析。患者根据治疗方法分成了三类:安慰剂组(n = 10

JACC:冠脉搭桥手术的当代预后优于以往

随着经皮冠脉介入治疗(PCI)技术的成熟,其预后也越来越好,但是外科治疗的预后变化情况尚不清楚。本研究的目的旨在比较评估目前接受冠脉搭桥手术(CABG)患者的预后和之前手术患者的预后。本研究对SYNTAX临床试验(2005-2007年)中的CABG患者和EXCEL临床试验(2010-2014)中的CABG患者进行了倾向性匹配分析,所有患者均有左主干冠脉疾病,伴有或不伴有多支冠脉病变。主要终点事件是

盘点:JACC四月第三期研究一览

1.慢性主动脉瓣反流患者的预后研究DOI: 10.1016/

JACC:经导管三尖瓣重建治疗中重度三尖瓣反流安全有效

严重的三尖瓣反流(TR)与高的死亡率相关,且治疗手段有限。本研究的目的旨在评估经导管三尖瓣重建系统在30例中重度TR患者中的6个月安全性和有效性。本研究纳入了TRI-REPAIR临床研究中的30例中重度、有临床症状的且不适外科手术治疗的TR患者,并对患者术前及术后6个月的临床、功能和超声心动图资料进行分析。患者的平均年龄为75岁,女性占73%,23%患者有缺血性心脏病,在基线水平,有83%的患者的